SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst significant price declines, driven by broader crypto market weakness and anticipation of the Bank of Japan's interest rate decision. Community sentiment is polarized, with many expressing frustration over persistent drops, while strong proponents emphasize institutional accumulation and buying the dip, confident in its long-term utility for global financial infrastructure.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is a top trending stock following its latest earnings report, which, despite beating estimates, sparked a significant market downturn due to cautious forward guidance and concerns over slowing sales in China and the impact of tariffs. Community discussions highlight strong disappointment with management's conference call performance, yet many investors are actively debating if this sharp decline represents a compelling long-term buying opportunity.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is a focal point following a Federal Reserve rate cut and upcoming Treasury bill purchases, which some in the community expect to fuel a rally in long bonds. Yet, considerable skepticism persists, with many observing that long-term yields are resisting downward pressure due to ongoing inflation concerns, questions about recent economic data's accuracy, and broader implications from central bank policy shifts including a potential new Fed chair. This creates a volatile environment as investors weigh easing efforts against market fundamentals.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending after reports confirmed a binding agreement for a US joint venture involving TikTok's operations, with Oracle joining as a key investor and cloud provider. This news is fueling bullish sentiment, as many investors believe it significantly validates Oracle's cloud infrastructure and AI strategy, potentially outweighing recent debt concerns. Conversely, some in the community remain cautious, continuing to highlight the company's substantial debt load and questioning the long-term financial upside of the deal.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending due to an announced all-stock merger with fusion power company TAE Technologies, valued over $6 billion. This significant strategic pivot from social media to the speculative clean energy sector has ignited intense community debate, with bulls anticipating future growth and skeptics fearing dilution or a "pump and dump." Investors are closely watching the implications of this move into a highly experimental industry.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending with significant momentum, primarily driven by high anticipation for an imminent NASA Lunar Terrain Vehicle (LTV) contract award, coupled with recent bullish analyst coverage and strong trading volume. The community is actively discussing LUNR's strategic advantage in lunar infrastructure, the potential for a substantial short squeeze, and broader market optimism for the space sector following an executive order on American space superiority.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending due to recent analyst upgrades, including a new "Buy" rating and an $18 price target from Benchmark, fueling investor optimism. The community is highly anticipating strong Black Friday sales results and discussing the company's long-term growth potential within the expanding African e-commerce market, despite acknowledging past volatility.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending amidst intense community debate, as a broader crypto market downturn fuels discussion over persistent price suppression and perceived market manipulation. Despite ongoing developments like new council members and enterprise integrations for real-world assets, investors are sharply divided between accumulating at current levels and anticipating further declines. The conversation revolves around HBAR's long-term utility in a compliance-first environment versus short-term market volatility and macroeconomic pressures.

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Athira Pharma Inc

Athira Pharma is trending following its announcement of exclusively licensing a late-stage breast cancer drug program and securing substantial financing to advance its development. This news has ignited significant trading volume, with many anticipating a potential short squeeze fueled by the low float, while others express caution regarding potential dilution and the stock's historical volatility.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries (GTBIF) is a major trending topic as the cannabis sector anticipates pivotal regulatory shifts, including potential federal rescheduling to Schedule III and recent actions clarifying the hemp market. Despite some initial market volatility seen as a 'sell the news' reaction, the community largely views these developments as monumental catalysts, highlighting GTBIF's strong financials and market leadership as key factors for substantial long-term growth driven by tax relief and future institutional investment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to the company, preliminary analysis of the data showed a 72% reduction in CRBSI and a 70% reduction in secondary hospitalizations.&nbsp;</li><li>The study was based on results from approximately 7,000 patients who received at least one dose of DefenCath in Year 1.</li><li>The latest DefenCath results indicate meaningful risk reduction among some of the most vulnerable patients and significant cost reductions, the company said.</li></ul>CorMedix Inc. (<a href="https://stocktwits.com/symbol/CRMD">CRMD</a>) stated on Thursday that its DefenCath, a catheter lock solution, had fewer catheter-related bloodstream infections (CRBSI) and secondary hospitalizations in adult dialysis patients as shown in its ongoing real-world interim study conducted in conjunction with U.S. Renal Care.The use of DefenCath resulted in a 72% reduction in CRBSI and a 70% reduction in hospitalizations secondary to CRBSI in the preliminary analysis of interim data for approximately 7,000 patients who received at least one dose of DefenCath in Year 1, the company said.Shares of CRMD were up over 2% on Thursday morning.<h2 class="st-heading-2">DefenCath Solutions</h2>CorMedix said that it believes the latest results about DefenCath indicate a meaningful risk reduction among some of the most vulnerable patients. The biopharmaceutical company added that it would also significantly save costs for the healthcare community.Centers for Medicare &amp; Medicaid Services (CMS) spends more than $3 billion per year on costs associated with CRBSI, with the average CRBSI-related hospitalization estimated to cost between $63,000 and $110,000 per incident, approximately, the company said.Joseph Todisco, CEO at CorMedix, said the interim results from the study will be used to support broader adoption of DefenCath and advance long-term reimbursement discussions, including with Medicare Advantage.“Our organization is deeply committed to advancing innovative therapies for our patients, and we are encouraged by the reduction in both serious infections and hospitalizations demonstrated in these preliminary results,” said Geoffrey A. Block, Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around CRMD jumped to ‘bullish’ from ‘bearish’ levels over the past day, and message volume changed to ‘normal’ from ‘low’ levels.<figure class="image"><img style="aspect-ratio:1274/160;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_18_at_9_42_40_PM_png_b7b4e3b880.webp" alt="On Stocktwits, the retail sentiment around CRMD jumped to ‘bullish’ from ‘bearish’ levels over the past day, and message volume changed to ‘normal’ from ‘low’ levels." width="1274" height="160"></figure> Shares of CRMD are up over 44% over the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is CorMedix Stock Rising Today?

CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study.

Equity

CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study. 

SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag

Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.

PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset

Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.

CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?

CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.

GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment

GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.

RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know

Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.

FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug

Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.

Squarepoint Ops LLC Purchases 224,412 Shares of CorMedix Inc $CRMD

Squarepoint Ops LLC raised its position in CorMedix Inc (NASDAQ:CRMD - Free Report) by 337.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer

AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.84	--	--	N/A
Q3 '25	$0.63	$1.26	98.65%	BEAT
Q2 '25	$0.19	$0.29	54.96%	BEAT
Q1 '25	$0.26	$0.30	15.38%	BEAT
Q4 '24	$0.13	$0.22	67.09%	BEAT

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CRMD News

CRMDCorMedix Inc